30
CARDIOVASCULAR
hamburger

About HeartMate 3 LVAD

The HeartMate​ 3™​ Left Ventricular Assist Device (LVAD) is a mechanical circulatory support device designed for patients with advanced heart failure. With significantly improved outcomes and survival comparable to heart transplant at 2 years, our LVAD technology is making a better future possible for many patients with advanced heart failure.*1-3 The HeartMate​ 3 LVAD has advanced the field of LVAD therapy and is setting the standard with innovation and outstanding clinical outcomes.1

The Full MagLev™ Flow Technology within the HeartMate 3 LVAD maintains gentle blood handling to minimize complications and hemocompatibility-related adverse events.

HeartMate 3 LVAD with Full MagLev Flow Technology offers:

  • Fully levitated, self-centering rotor, which does not require hydrodynamic or mechanical bearings
  • Large, consistent blood flow pathways, which reduces shear stress4
  • Intrinsic pulsatility, which reduces stasis and minimize thrombus4,5
Cut across view of the HeartMate 3 Maglev Pump

HeartMate 3 LVAD Clinical Evidence

There are comprehensive clinical evidence materials available to learn about the survival rate and patient improvement associated with the HeartMate 3 LVAD. For a deep dive into the clinical data, visit the Clinical Evidence and Journal Article information.

Highlights from Long-Term MOMENTUM 3 Study

In the largest LVAD trial ever conducted, clinicians studied the safety and effectiveness of the HeartMate 3 LVAD in patients with advanced heart failure and who were indicated for mechanical circulatory support with an LVAD. The study showed:

HeartMate 3 LVAD shows 79% 2-year survival rate for adult heart transplant patients between 2009 and 2015.
80% of patients saw sustained improvement through 2 years.

Improved Safety Profile

Lowest hemocompatibility-related adverse events of any LVAD§*1,8-10

10% stroke 1% thrombosis after HeartMate 3 LVAD implant.

HeartMate 3 LVAD Education and Training

For the safe and effective management of advanced heart failure with the HeartMate 3 LVAD, we provide comprehensive educational resources. The following resources are designed to help you better understand patient education, use cases, surgical procedure and more.

This device is commercially available for use in select international markets.

*Based on published data from separate datasets, which may involve different patient populations and other variables. Not a head-to-head comparison. Data presented for informational purposes only.

§For a continuous-flow LVAD in a randomized controlled trial.

References

  1. Mehra M, Uriel N, Naka Y, et al. A Fully Magnetically Levitated Left Ventricular Assist Device-Final Report. N Engl J Med. 2019;380:1618-1627.
  2. Khush KK, Cherikh WS, Chambers DC, et al. The International Thoracic Organ Transplant Registry of the International Society for Heart and Lung Transplantation: Thirty-fifth Adult Heart Transplant Report-2018; Focus Theme: Multiorgan Transplantation. J Heart Lung Transplant. 2018;37:1155-1168.
  3. Teuteberg JJ, Cleveland JC Jr, Cowger J, et al. The Society of Thoracic Surgeons Intermacs 2019 Annual Report: The Changing Landscape of Devices and Indications. Ann Thorac Surg. March 2020;109(3):649-660.
  4. Bourque K, Cotter C, Dague C, et al. Design rationale and preclinical evaluation of the HeartMate 3 Left Ventricular Assist System for hemocompatibility. Am Soc Artificial Int Organs. 2016;62:375-383.
  5. Bourque K, Dague C, Farrar D, et al. In vivo assessment of a rotary left ventricular assist device-induced artificial pulse in the proximal and distal aorta. Artificial Organs. 2006;30:638-642.
  6. Abbott data on file.
  7. Mehra MR. A Fully Magnetically Levitated Left Ventricular Assist Device-Final Report for the MOMENTUM 3 Trial. American College of Cardiology (ACC) Annual Meeting; March 17, 2019; New Orleans, LA.
  8. Rogers JG, Pagani F, Tatooles A, et al. Intrapericardial left ventricular assist device for advanced heart failure. New Engl J Med. 2017;376:451-460.
  9. Markham DW. Two-year Outcomes in the ENDURANCE Supplemental Trial. American Heart Association (AHA) Annual Meeting; November 10, 2018; Chicago, IL.
  10. Uriel N. Long-Term Burden of Hemocompatibility Related Adverse Events in the MOMENTUM 3 Trial: Final Analysis of the 1028 Patient Cohort. The International Society for Heart & Lung Transplantation (ISHLT) Annual Meeting; April 4, 2019; Orlando, FL.

MAT-2106243 v1.0

DO YOU WISH TO CONTINUE AND EXIT CARDIOVASCULAR.ABBOTT?

CONTENTS OF THE SITE ARE NOT UNDER THE CONTROL OF ABBOTT.

False
accessibility
© 2016 Abbott. All Rights Reserved. Please read the Legal Notice for further details.

Unless otherwise specified, all product and service names appearing in this Internet site are trademarks owned by or licensed to Abbott, its subsidiaries or affiliates. No use of any Abbott trademark, trade name, or trade dress in this site may be made without the prior written authorization of Abbott, except to identify the product or services of the company.

accessibility

DO YOU WISH TO CONTINUE AND EXIT CARDIOVASCULAR.ABBOTT?

CONTENTS OF THE SITE ARE NOT UNDER THE CONTROL OF ABBOTT.